Treating early stage 1 type 1 diabetes in children with cell therapy and antibody
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be between 3 and 18 years old and weigh at least 44 pounds (20 kg).
- Must have positive antibodies (at least two different types) that show the immune system is attacking the pancreas.
- Must still produce a normal amount of insulin (fasting C-peptide at least 1.0 ng/mL) and have normal blood sugar levels.
- Cannot have used any diabetes medications, including insulin, in the past 4 weeks.
- Child must not have any other autoimmune diseases, like Hashimoto's or celiac disease.
- Must be able to come to appointments and receive intravenous treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This trial tests an experimental gene therapy using your own stem cells to treat early type 1 diabetes. It aims to preserve insulin-making cells and potentially reduce your need for insulin.
This study tests a new immune therapy using your own modified cells to try to stop type 1 diabetes from getting worse. It is for young adults who were recently diagnosed and still make some insulin.
This trial tests a medicine called anti-thymocyte globulin (h-ATG) to see if it can help people with type 1 diabetes keep making some of their own insulin. It may slow the loss of insulin-making cells and help manage blood sugar.
Hear when a new Presymptomatic Diabetes Type 1 (Stage 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.